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Abstract 
Context To successfully compete for future patients, fertility specialists strive to 
achieve high pregnancy rates. If the specialist transfers multiple embryos during 
an in vitro fertilization (IVF) procedure to obtain high pregnancy rates, the 
percentage of high order multiples (HOM) may inadvertently rise. 
~--
Objective To measure the effect of competition among fertility centers on 
outcomes in in vitro fertilization. 
Design and Setting Retrospective cohort of 408 fertility clinics registered with 
the Society for Assisted Reproduction as providing IVF services in 2000. 
Competition is defined as number of clinics in a statistical area. Demand for 
services is based on the population of reproductive aged women. 
Subjects 381 fertility clinics reporting clinical outcomes 
Main outcome measures: The clinic high order multiple gestation rate 
(percentage of pregnancies that were high order multiples) and age adjusted 
pregnancy rate 
Results The number of clinics in an area of competition ranged from 1-22. 
HOM rate per clinic ranged from 0% to 50%. As demand increased, competition 
increased. As competition increased the number of high order multiples per clinic 
decreased. In areas of low competition (1-2 clinics) the clinic rate was 8.46%, in 
areas of intermediate competition (3-7 clinics) 8.39%, and in areas of high 
competition (8-22 clinics) 8.24%. In areas with intermediate demand, high levels 
of competition resulted in fewer high order multiples than intermediate 
competition (RR 0.56, 95% confidence interval 0.36,0.89) or low levels of 
competition (RR 0.57, 95% confidence interval 0.35, 0.94). Age adjusted 
pregnancy rates did not differ by level of competition. 
Conclusions Based on this data, the risk of high order multiple gestation 
decreases with increasing competition between clinics; however, pregnancy rates 
are unaffected. 
2 
Acknowledgements: 
Katherine E. Hartmann, MD, PhD: Second reader, provided editing and advice on 
methodology 
Vijaya K. Hogan, PhD: Advisor, provided extensive editing 
Bob Konrad, PhD: Consultant, provided advice on defining a geographical area 
L 
'-
I 
3 
Problem Statement 
In the year 2000, 180.5 out of 100, 000 live births were triplets or other 
high order multiple births. Although this number is down from its peak of 193.5 
in 1998, it is still significantly higher than the 1980 rate of371 These multi-fetal 
pregnancies are associated with adverse fetal implications such as prematurity, 
and maternal complications such as pre-eclampsia and uterine atony with 
hemorrhage. In addition, there are large health care costs associated with the 
multi-fetal pregnancy and its related complications2 Preventing high order ~---
multiple pregnancies can reduce costs and decrease both maternal and infant 
mortality. 
The use of assisted reproductive technology (ART) services, such as 
intrauterine insemination, ovarian hyperstimulation, and in vitro fertilization 
(IVF) is associated with an increased risk of multi-fetal pregnancy2 In 1998, 
11% ofiVF pregnancies were high order multiples (HOM), three or more 
gestaiions3 In fact, ART accounts for 43% of the total number of HOM births in 
the United States4 •5 
The association between HOM and IVF is especially concerning 
considering the large demand for infertility services. Approximately 1.2 million 
women received care for infertility in 1995 6 Many of these women sought ART 
services. By 1998, 27,300 (0.7%) of the 3.9 million births in the United States 
were the result of ART 2 
4 
Background 
Previous Literature 
Several researchers have hypothesized and studied risk factors for high 
order multiple pregnancies (See Attachment A). Different areas of research have 
included access to care, physician practice styles, system level interventions, 
patient demographics and medical history, and patient attitt1des. Few researchers 
have stt1died the effects of access to care on the rate of high order multiples. Jain 
et a!. found that mandated insurance coverage for IVF lead to a decline in the 
percentage ofHOM7 However, other researchers failed to find such an 
association8 
The medical history of a patient may also contribute to the risk ofHOM. 
Some authors have found that increasing number of previous attempts at IVF 
resulted in a lower risk of multiple gestation9 '10 However, Basil eta! did not 
observe this association in a retrospective study. 11 Studies researching the effects 
of age have been even more inconsistent, with some studies finding that age 
decreases the risk ofmultiples,9•12•13 and others showing that age has no 
association. 11 •14 In fact, Senoz et a! found a nonsignificant trend of increasing risk 
with age. 15 These differences may more reflect physician practice styles than a 
medical risk factor. Physicians transfer more embryos in older women than 
younger women, however the difference in the numbers transferred varies by 
physician. 
Embryologic factors are a more frequently studied subject. Multiple 
articles have shown a significant association between number of embryos 
transferred and risk ofHOM. 10•1t.tJ-ts However, these studies differed in their 
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recommendations on the number of embryos to transfer, two or three, to 
maximize pregnancy rates and minimize the mLI!tiple risk. On the other hand, two 
studies have clearly shown that blastocyst transfer can lead to lower multi-fetal 
pregnancies 16' 17 One study showed that increased embryo quality led to a higher 
risk of multiples, but this study has not been confirmed. 11 Finally this same study 
showed that the total number of embryos generated was not associated with HOM 
risk. Clearly the evidence on risk factors for high order multiples is not 
conclusive. 
Hock et al used a survey to assess the role of physician practice patterns 
on multi-fetal pregnancies. 18 He found that providers varied in their choice of 
ART, IVF or superovulation, by region in the United States. In addition, he found 
that almost all physicians used informed consent for reproductive procedures. 
The majority of physicians discussed selective reduction (98.3%) and the 
complications associated with multiple gestation. Physicians most commonly 
cited maternal morbidity, preterm labor, fetal neurologic sequelae, and fetal death 
as the complications of multiple gestation pregnancies. These discussions may 
influence patient knowledge and attitudes towards HOM. 
Goldfarb eta! assessed patient's attitudes towards multiple pregnancies by 
interviewing couples currently undergoing ART. 19 He found that patients 
preferred triplets to no pregnancy in 88%-98% of cases, and 56-78% preferred 
quadmplets to no pregnancy. Interestingly, attitudes toward HOM varied by 
choice of ART procedure. 
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To reduce the adverse consequences of HOM, the American Society for 
Reproductive Medicine published guidelines in 1999 on the appropriate number 
of embryos to transfer. These guidelines stress the use of informed consent and 
provide guidance on the number of embryos to transfer based on age, prognosis, 
and donor status20 The subsequent decline in HOM would imply that these 
guidelines have been successful. The rate ofiVF pregnancies that are high order 
multi-fetal gestations dropped from 11% in 1998 to 7. 7% in 2000.21 Engman et a! 
found that legislation limiting the number of embryos transferred to three, failed 
4---
to significantly reduce the risk of mnltiple birth in England9 
Current Research Needs 
In 1992, the Fertility Clinic Success Rate and Certification Act (P.L. 102-
493) called for the reporting and publicizing of the pregnancy rates from all 
fertility clinics. These success rates are obtained and validated by the individual 
clinics and published on the World Wide Web by the Centers for Disease Control 
and Prevention (CDC), with consultation from the American Society for 
Reproductive Medicine, Society for Assisted Reproductive Technology, and 
RESOLVE: The National Infertility Association.21 These published success rates 
appear to influence a patient's choice of a fertility clinic more than the price of the 
IVF therapy, distance of the clinic from home, opinion of friends about the clinic, 
or recommendation of a general practitioner or gynecologist.22 Thus, a high 
pregnancy success rate is important for both economic reasons and the reputation 
of the clinic. The goal of achieving pregnancy with each in vitro fertilization 
attempt may lead physicians to transfer multiple embryos. 
7 
Does competition for success amongst fertility clinics indirectly result in 
increased rates of high order multiples? Experts in the field of reproductive 
endocrinology have proposed anecdotally that competition between fertility 
clinics has induced physicians to transfer multiple embryos in order to improve 
23 24 25 A . . I I . . h I . . I success rates. · · n empmca ana ys1s to examme t e ro e compel!twn p ays 
in increasing the number of high order multiples is needed. This requires a 
-;---
methodologically sound means of measuring competition. 
Methodological Considerations in Measuring Competition 
A measurement of competition between fertility clinics has yet to be 
established. Therefore, a way of measuring competition for each clinic must be 
L 
generated. In a review on measuring competition in health care by Baker in 2001, 
the author stresses the need to consider 5 conceptual issues when studying 
competition: 1) a definition of the product under study, 2) a measure of 
competition, 3) a definition of the market, 4) identification of forces that modify 
market dynamics, and 5) the role of health maintenance organizations. 26 
Research previously cited on quantifying the degree of competition, uses a 
variety of measures for market competition. The number of firms/hospitals (N) in 
a market area can be counted and used as a measure of competition in that market 
area. Robinson and Luft counted the number of hospitals within 15 miles of each 
other, and used the number, N, as the measure of competition27 Gift et a! and 
Dranove et a!. considered all hospitals within the same metropolitan area as the 
number, N?8·29 Although this method is commonly used and easily implemented, 
it fails to take into consideration the relative sizes of firms. 
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The Herfindahl-Hirschman Index (HHl), another measure of competition, 
is calculated by taking the sum of squared firn1 market shares in an area [(percent 
market share for clinic A)2+(percent market share for clinic B)2+ ·· .] 28 Market 
shares for hospitals are usually assigned based on hospital discharges. HHI 
considers both the relative size and distribution of the firms in a market. As the 
number of firms increases or the share of the market becomes more evenly 
distributed, HHI approaches zero, thereby representing high levels of competition. 
The Federal Trade Commission uses the HHI measurement for anti-trust 
monitoring. 
Another way to define competition is to quantify the extent to which two 
hospitals/firms' markets overlap. The market of a hospital is defined by the zip 
codes of those patients discharged from the hospitaL Zwanzinger and Melnick 
used a ZIP code-based HHI to measure competition in multiple studies.30·31 Sohn 
also used zip codes to define and compare overlap between hospital markets in 
the Los Angeles area using a method defined as the relational approach32 L 
How do the various methods of measuring competition compare? 
Bernstein and Gauthier point out that there is no consensus agreement on the 
perfect method of measuring competition33 Many previous analyses of 
competition have been undertaken for a wide variety of reasons by academic 
researchers, policymakers, competitors, and payers. Their definitions of 
competition varied by the needs and perspective of the researcher. Bernstein and 
Gauthier further state that all commonly used measures can be criticized for their 
inability to capture the true nature of competition. Most markers fail to capture 
9 
local market conditions, such as patient allegiance to certain hospitals or provider 
groups, restrictions on HMO referrals, or perceived competition by the firrn 
management33 Sohn found that the various measurements of competition varied 
significantly in the geographic area she studied with only 50% concordance 
between any two methods. She asserts that theN method or radial approach 
overestimates the level of competition in urban markets and underestimates it in 
rural areas32 However, Garnick et a!. found that all methods produced 
bl f . . ~ compara e measurements o competJtwn. 
Many geographic areas have been used to define health care markets. 
Robinson and Luft drew a fixed radius, 15 miles, around each firrn to define an 
area. Unfortunately a 15-mile radius in Boston, MA may not be similar to a 15-
mile radius in Greensboro, NC. Fisher and Wennberg35 used the Dartmouth Atlas 
ofHealthcare, which defines 306 hospital referral regions based on patient travel 
patterns. Brasure et al used Health Service Areas (HSA)36 to analyze competitive 
behavior among physicians. 37 Health service areas are defined using 1988 
Medicare data on short hospital stays. There are four alternative definitions of 
HSAs, two of which base the definition of a HSA on metropolitan statistical 
areas. 36 
Metropolitan statistical areas (MSA) have a large population nucleus with 
surrounding communities that share a high degree of economic and social 
integration with the core. MSAs are established by the Office of Management 
and Budget using set standards. Each MSA must have one city with 50,000 or 
more inhabitants and a total metropolitan area of at least 100,000. Counties are 
10 
the components ofMSAs. In MSAs with populations greater than one million the 
area can be divided up into Primary Metropolitan Statistical Areas (PMSAs) only 
if the counties in the PMSAs are highly economically and socially integrated38 
Other researchers have used metropolitan statistical areas to define a 
health market. Deaton and Lubotsky compared mortality rates between MSAs39 
Anderson et a!. used MSAs to compare community wide access to medical care40 
Hendryx et a! compared social capital and access to medical care among 22 
MSAs41 
Thus a number of factors need to be considered when measuring 
competition in health care markets. Previous studies offer a variety of 
measurements of competition and geographically defined market areas. Because 
competition among fertility centers has yet to be defined or quantified, previously 
applied methods of measuring competition must be adopted. 
Methods 
Study Question 
This study analyzes the effect of competition among fertility centers on 
outcomes in in vitro fertilization, specifically high order multiples and pregnancy 
rates. We hypothesize that competition between clinics results in higher rates of 
HOM and higher pregnancy success rates. (H0=competition has no effect on 
outcomes or decreases the number of HOM) The alternative hypothesis is that 
competition between clinics results in higher rates of high order multiples and 
higher success rates. 
11 
Data Source 
The total number of high order multiple pregnancies occurring from fresh 
embryos with non-donor eggs is currently available from the 2000 Assisted 
Reproductive Technology Success Rates accessible from the world wide web.21 
These success rates are published and placed on the World Wide Web by the 
Centers for Disease Control and Prevention.21 All clinics that provide artificial 
reproductive services are required by law to submit their pregnancy rates to the 
Society for Assisted Reproductive Technologies (SART). The clinic directors 
then verify the data. SART maintains a list of all ART clinics and their reported 
success rates and releases that data to the CDC. From 1995-1999 the CDC 
conducted on-site validation visits, where they randomly selected records from 
1321 cycles in 29 clinics. The discrepancy rate was found to be less than five 
percent. Starting with the 2000 report, the CDC did not conduct random 
validation visits. Instead, SART conducted a clinic-specific self-validation 
process. Two hundred and ten of the 377 clinics contacted (63%) completed the 
self-validation worksheets and a total of2098 ART cycles were validated. 
Discrepancy rates were calculated and found again to be low. The weighted 
discrepancy rate for number of fetal hearts on ultrasound was 3 .3 %. 21 In 1999 the 
4? 
reported rate was 3%. -
Only HOM pregnancies occurring from fresh non-donor eggs were 
studied. HOM pregnancies occurring from frozen embryos or donor eggs are not 
reported by the CDC. Twin pregnancies, although reported by the CDC, are not 
included as high order multiples. The percentage oflive births with multiple 
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infants underestimates the number of pregnancies with multiple fetuses. Patients 
may choose to selectively reduce multi-fetal pregnancies, thus decreasing the 
number of multi- fetal pregnancies delivered. 
Population 
The unit of analysis for this study is the clinic. All fertility clinics listed 
by the Society for Assisted Reproductive Technology as providing IVF services 
in 2000 in the United States, including Puerto Rico, are included. On the list were 
408 clinics. All 408 were included in the calculation of competition. Twenty-five 
of the 408 clinics (6%) failed to submit and validate their clinic data, and 
therefore were not included in the analysis. In addition, clinics that provide the 
majority of their care to military families were excluded from the analysis. These 
two clinics were Wilford Hall Medical Center and The ART Institute of 
Washington, Inc. at Walter Reed Army Medical Center. This left 381 clinics in 
the final analysis. 
Independent and Dependent Variables 
The outcomes analyzed were 1) HOM rate, percentage of HOM 
pregnancies per pregnancy event over one year and 2) age adjusted pregnancy 
rate, number of pregnancies/number of initiated cycles over one year and 3) 
average number of embryos transferred. Data on in vitro fertilization outcomes 
were extracted from the 2000 Assisted Reproductive Technology Success Rates 43 
For each clinic, number of initiated cycles by age group, pregnancy rate by age 
group, average number of embryos transferred by age group, and HOM rate by 
age group were recorded. Initiated cycles are the total number ofiVF cycles 
13 
summed across all patients started at a clinic. Total pregnancies, total number of 
HOM pregnancies, and clinic HOM rate were calculated from this data and used 
for analysis. In addition, an age adjusted pregnancy rate was calculated for each 
clinic using the national age distribution to adjust for the differing age structure 
among clinics. 
Competition 
Competition was the main independent factor studied. It was defined as 
the number of clinics providing IVF services in the delineated market area. For 
this paper we have chosen to use metropolitan statistical areas (1990 standards) as 
the geographic market. The addresses for reporting and non-reporting clinics 
were downloaded from the CDC website. Using the zip codes for each clinic, the 
county and its designated MSA and, if applicable, its PMSA were obtained. The 
area of competition was defined as the PM SA. If the clinic was not located in a 
PMSA, the MSA was defined as the area of competition. If a MSA was not 
available, the county was defined as the area of competition. 
The number of clinics in each area of competition was calculated and 
then categorized. Areas with I to 2 clinics were defined as displaying low levels 
of competition, 3 to 7 clinics as intermediate competition, and greater than 7, high 
competition. This level of competition was then assigned to each clinic within 
that area. 
Covariates 
Demand 
Demand is defined as the universe of all potential users of IVF services. 
Densely populated urban areas may be able to accommodate more than one 
14 
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fertility center. Although centers in these areas compete for patients, the demand 
for services may be greater, thus mitigating the competitive pressure. 
Demand for services was based on the female population between the ages 
of25 and 44 in each area of competition. 98.3% of all women seeking in vitro 
fertilization in 2000 were in this age range.43 The population of these women in 
each area of competition (MSA, PMSA, or county) was obtained using the 2000 
census.
44 Demand was categorized, where clinics in areas with a population less 
than 130,000 females were assigned a low score and clinics in areas with a 
population with greater than 600,000 females was assigned a high score. Clinics 
L 
in areas with numbers between these two were assigned an intermediate score. 
Cutoffs for high and low levels of demand and competition were based on the 
twenty-fifth and seventy-fifth percentiles. 
Insurance 
The final independent variable delineated whether insurance covered IVF 
services in the clinic's location. Clinics were categorized in three groups: full 
insurance coverage mandated, partial insurance coverage mandated, or no 
insurance coverage mandated. 
Statistical Analysis 
Statistical analysis was performed using STAT A 7.0 statistical software 
(College Station, TX). First, the mean HOM and pregnancy rate for each level of 
competition stratified by level of demand was calculated. HOM rate was not 
normally distributed. We transformed HOM by taking the square root. 
Pregnancy incidence was normally distributed. With these two normally 
15 
distributed outcomes, two way ANOV A was used to test equality of the means 
between levels of competition and demand. P-values less than 0.05 were 
considered significant. 
Next, an analytic model was constructed to study the effect of competition 
on HOM within each level of demand. Eight combinations of competition and 
demand were coded using indicator variables, with low competition in an area of 
low demand as the referent indicator. Indicators for areas with high competition 
and low demand and areas with low demand and high competition were not 
included in the model because of zero observations in these groups. Also 
insurance coverage was coded using two indicator variables with no mandated ! 
L 
insurance as the referent indicator. We constructed the following model: 
HOM rate= a +{J;X;+IJZj+residual 
rx= intercept, {J;=additional risk of HOM associated with X; level of demand and 
competition, i=l,2,3 .. 7 (e.g. X1=1 if observation in a area with low competition 
and intermediate demand and X1=0 otherwise), IJ= additional risk of HOM 
associated with Zj type of insurance coverage mandated, j=l,2 (e.g. Z1=1 if partial 
coverage for IVF mandated, 0 otherwise) 
Because HOM rate was not normally distributed, linear regression 
analysis was inappropriate. Poisson regression appeared more appropriate; 
however, an important assumption in Poisson regression is that the variance 
equals the mean. Because over-dispersion was noted for our outcome (HOM 
mean 4.58, variance 43.4), we used negative binomial regression, which adds a 
random effect to represent unobserved heterogeneity, correcting for the extra 
16 
variance 45 Using negative binomial regression with the number of HOM in a 
clinic as the dependent variable and number of pregnancies in each clinic as the 
exposure, combinations of competition and demand as the independent variables, 
and insurance status as the covariate, relative risks were calculated. 
A second regression model was constructed to evaluate the association 
between competition and pregnancy rate using the same model in the HOM 
analysis. However linear and log linear regression were used to calculate adjusted 
relative risks and adjusted risk differences. 
Only the average number of embryos transferred for women 38-40 was 
normally distributed. For this reason, only this age group was selected to study 
the effect of competition on the number of embryos transferred. Categorical 
variables for competition, demand, and insurance and a continuous variable for 
embryos transferred were created. A third model was constructed. 
a= intercept, ~ 1 =percent change in embryos transferred per increase in one level 
of competition (X), ~2= percent change in embryos transferred per increase in one 
level of demand (Z1), ~3=percent change in embryos transferred with a change 
insurance mandate (Z2) 
Linear regression was used to obtain the percent change in embryos transferred 
per increase in one level of demand. 
Results 
The number of clinics in each area of competition ranged from 1 to 22. 
The population base of reproductive age women in the market areas ranged from 
17 
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2,677 to I ,557,904. One hundred three clinics (25%) were located in areas with 
fewer than 130,000 female residents between the ages of25 and 44, 101 (25%) in 
areas with greater than 600,000, and 204 with numbers in between. The 
percentage of HOM for individual clinics ranged from 0 to 50% (mean, 8.36). 
As demand for services increased, the number of clinics in the area 
increased. In areas with less than 130,000 women, the number of clinics averaged 
1.65 (Standard deviation, 0.801). In areas with greater than 130,000 women but 
less than 600,000 there were 4.59 (standard deviation, 2.16). In areas with greater 
than 600,000 women, the number of clinics averaged 15.65 (standard deviation 
5.62). 
Mean clinic HOM rate declined as the level of competition increased 
(two-way ANOV A p=0.006). Mean percentage for low level of competition was 
8.43%, intermediate 8.39%, and high 8.24%. Level of demand increased as the 
proportion of HOM declined (two-way ANOV A p=0.002). Mean percentage for 
low level of demand was 7.69%, intermediate 8.22%, and high 9.33%. 
Table I. Mean HOM rate among fertility clinics by level of competition and 
demand (standard deviation), 2000 
Level of competition 
1 2 3 Overall 
(1-2 (3-7 (8-22 
clinics) clinics) clinics) 
Level 1 8.05 4.55 7.69 
~-
(low) (6.37) (5.94) (6.39) 
Of 2 9.45 8.29 5.53 8.22 
(intermediate) (9.61) (6.17) (7.98) (7.07) 
Demand 3 13.60 8.82 9.33 
-
(high) (14.09) (7.46) (8.43) 
Overall 8.43 8.39 8.24 8.36 
(7.37) (7.02) (7.61) (7.27) 
18 
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After adjusting for level of demand and insurance coverage, clinics with 
higher levels of competition were significantly more likely to have a lower HOM 
percentage compared clinics with low levels of competition or clinics with 
intermediate levels of competition in areas of intermediate demand. 
Table 2. Measures of Association between HOM and competition among fertility 
clinics stratified by level of demand, 2000 
Level of Level of Relative Risk Relative Risk* 
Demand Competition (95% Confidence (95% Confidence 
Interval) Interval) 
Low Intermediate 0.71 (0.39, 1.29) 0.69 (0.38, 1.25) 
competition versus 
low competition 
Intermediate Intermediate 1.02 (0.80, 1.31) 1.02 (0.80, 1.29) 
competition versus 
low competition 
High competition 0.59 (0.36, 0.97) 0.57 (0.35, 0.94) 
versus low 
competition 
High competition 
versus intermediate 0.58 (0.37,0.91) 0.56 (0.36, 0.89) 
competition 
High High competition 1.03 (0.68, 1.56) 1.09 (0.718, 1.65) 
versus intermediate 
competition 
*Adjusted for msnrance status 
The age adjusted pregnancy rate did not differ significantly between the 
levels of demand (Two-way ANOV A, p=0.481) or levels of competition (Two-
way ANOV A, p=0.872). No statistically significant adjusted measures of 
association were found between levels of competition within a level of demand. 
Average number of embryos transferred in women ages 38-40 did appear to 
significantly rise with an increase in each level of competition (RD 0.1 0%, 95% 
CI 0.012, 0.197). However, after adjusting for level of demand and insurance 
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status the effect of competition was even smaller and failed to be significant (RD 
0.07%, 95% CI -0.095,0.239). 
Table 3. Age adjusted pregnancy rate for fertility clinics (standard deviation), 
?000 
-
Level of competition 
1 2 3 Overall 
(1-2 (3-7 (8-22 
clinics) clinics) clinics) 
Level 1 28.09 26.46 27.92 
--
(low) (10.43) (10.84) (10.43) 
Of 2 28.41 31.82 29.75 31.05 
(intermediate) (9.70) (9.84) (10.91) (9.95) 
Demand 3 27.01 29.60 29.32 
--
(high) (8.04) (11.35) (11.04) 
Overall 28.17 31.19 29.62 29.83 
(1 0.2) (9.89) (11.22) (10.41) 
Discussion 
The results of this study suggest that competition is associated with a 
lower risk of high order multiples. These findings contradict the previously 
hypothesized relationship between competition and HOM that an increase in 
competition would lead to greater HOM. However, no other studies have 
attempted to empirically quantify the effects of competition on HOM. 
To accept our conclusion, one must agree that the methodology of this 
study is valid. Specifically, one must assume that this measure of competition 
accurately depicts the degree to which competition actually is perceived and 
occurs among fertility centers. 
The number of clinics in a market area, a measure of competition, was 
selected mainly due to feasibility. A possible alternative measure would be HHI. 
The total number of cycles could be used to represent the market share of a clinic. 
20 
However, a number of clinics do not report their outcomes. A measure of 
competition could not be assigned for every market area with a non-reporting 
clinic, which would generate a large amount of missing data. Any imputation of 
their market share without further information on these clinics would add bias. 
There is some concern that a measure of competition snch as HHI that 
incorporates market share would more accurately describe competition among 
fertility centers. Previous research has shown that large hospitals generate more 
competition than small hospitals but that the size of the hospital does not affect 
the amount of competition received.32 This would imply that adjusting for 
market share in the measure of competition may be important. However, Baker 
L 
points out that the number of firms in a geographic area and HHI are typically t 
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correlated, suggesting that both measures of competition would likely produce 
r 
similar results26 
In addition, it is very important to use a valid geographic area for small 
area analysis. Unfortunately no gold standards exist, and researchers are limited 
by the available data. Defining a geographic area by drawing a set radius around 
a clinic fails to accommodate for differences in urban and rural regions. 
Geographic areas used in previous literature, such as HSAs, are inappropriate for 
fertility clinic analysis. HSAs have been generated using Medicare hospital data. 
IVF patients are younger than the Medicare population and use clinic not hospital 
services. In addition, IVF is infrequently covered by insurance. In that sense, 
IVF services are more similar to a commodity than a health service. Therefore 
21 
MSAs, which are defined by economic and social integration, are more 
appropriate choice for the geographical unit for this study. 
Our use of metropolitan statistical areas may be a poor substitute for the 
actual market for in vitro fertilization services. Without information from clinics 
about their patient base, we are unable to verify the appropriateness ofMSAs as a 
substitute. Research on the utilization of ART services would be improved by 
studies that look into catchement areas for individual IVF clinics. 
Also, the use ofMSA population to define demand may underestimate the 
actual demand. Eighty percent of the population in the United States lives in 
Metropolitan Services Areas46 However, women in metropolitan statistical areas 
without a fertility clinic (over 50%) and women not living in a MSA also seek 
fertility services. Future research may wish to elucidate the migration pattern for 
these regions. 
Although the majority of clinics are probably independent, some may be 
managed by one parent institution. It is unlikely that these clinics would compete, 
. 
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but would rather share patients and health care providers. We could not account 
for affiliated clinics in this analysis. However, we hypothesize that the number of 
these associations are relatively few. 
The fertility community generally accepts the CDC data set as valid for 
research. Jain et allooked at the interaction between the provision of insurance 
and pregnancy success rates and higher order multiple rates using the CDC data 
set7 In addition, authors in SART have used the data to correlate clinic volume 
with success rates3 •21 •42 Finally, Feigenbaum used the Fertility Clinic Reports to 
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study the use of homologous and donor embryos in women over forty47 
Reynolds eta! challenged this use of aggregate level data to study patient level 
outcomes. 8 Since our unit of analysis is the clinic and not the patient, we feel that 
aggregate level data are appropriate and valid. 
There is limited outcome information on those clinics not reporting their 
data. However, this is a small subset of the clinics. Of the 25 clinics that did not 
report in 2000, II clinics did not report in 1999, 6 reported in 1999 tmder the 
same name or in the same location, and 8 clinics were new to the list. The median 
HOM percentage for those clinics that did report in 1999 but not in 2000 was 
14.9%. The total number of cycles initiated per clinic reporting in 1999 ranged 
from 18-231. 
Establishing why certain clinics do not submit their data may improve the 
validity. Non-reporting clinics appear to be concentrated in areas of! ow 
competition, which may bias the results. If they perform few ART procedures, 
other clinics in the area may not see them as competition. If they have higher 
HOM rates, as implied by the few clinics that did report in 1999, the difference 
between areas with low versus high competition may be greater. However, more 
information would be necessary to validate this hypothesis. 
Currently, insuraBce companies do not cover IVF in the majority of states. 
-i--
Therefore this study did not seek to address the influence of health maintenance 
organizations on competition. If insurance mandates become more widespread, 
the role ofHMOs will have to be explored. It is not known if physicians will 
change their practice patterns to obtain contracts with HMOs. HMOs may use 
similar standards such as quality, success rates, and price to monitor clinics. 
The strengths of this study are in its measurement of competition and in 
the measurement of the outcomes. In addition, it adjusts for insurance coverage, 
which has previously been shown to influence not only competition but also 
HOM rates. Finally, it attempts to delineate the factors, such as number of 
embryos transferred that may be the intermediaries between competition and 
HOM. 
I theorized that competition between fertility centers would result in 
greater numbers of high order multiples. The results of this analysis do not 
L 
support this hypothesis. However, the implication that competition improves 
quality of care is not unique in healthcare. Kessler and McClelen found that high 
competitiveness resulted in lower mortality and complication rates after heart 
attacks48 An analysis by Sari in 2002 showed that increasing a hospital's market 
share, and subsequent decline in competition, resulted in a decline in qualit/9 
Why high order multiple rates decline in areas of high competition or in 
areas with fewer reproductive women, we can only hypothesize. Clinics with 
high levels of competition are not transferring significantly fewer or greater 
numbers of embryos. Perhaps education and guidelines by the American Society 
for Reproductive Medicine and the Society for Assisted Reproductive Technology 
on appropriate numbers of embryos to transfer have been successful. Instead of 
transferring greater numbers of embryos to improve pregnancy rates, physicians 
24 
may seek other means to increase pregnancy rates such as blastocyst transfers and 
more selective choice of candidates for TVF. 
Other authors have attempted to delineate the risk factors for HOM. 
Reducing the number of embryos transferred and using blastocysts have been 
shown to be potentially useful. However, this study tries to identify another 
means to intervene. Before encouraging further competition among clinics by 
sponsoring additional IVF clinic openings, we would suggest more research on 
physician's attitudes and practices in areas ofhigh competition. However, 
r--
competition should no longer be viewed as the culprit in NF. 
Most people recognize the negative impact that high order multiples can 
cause. It is imperative that we identify and quantify the factors that may 
contribute to this problem. Future efforts to curtail high rates will depend on 
recognizing and controlling factors in the health care system that contribute to this 
unintended outcome. 
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System Level Attachment A: 
SART oversight and A Model for the Influence of Local 
reporting Competition on Multiple Pregnancy 
Guidelines Rates among Patients with Infertility 
Provider Factors Patient Education 
Patient Beliefs Media coverage 
Access to Care Cost of the procedure Knowledge of Success Perceived urgency Type of clinic 
rates Cultural Beliefs Available Reproductive Level of training Past experience with IVF 
-
Willingness to participate Endocrinologist __,. Membership in SART ~ Available information Distance to IVF Center Local Competition 
on!VF in selective reduction Likelihood of success Financial incentives Abilitv to uav Perception of personal and 
/ + . - Selective Reductwn + 
Oocytes retrieved Embryo's !Tansferred I ..... Multiple Pregnancy rate Stimulation Protocol 
IVF versus COH 
J . ~ L_ / 
Medical History 
VF= In vitro fertilization Type oflnfertility 
Embryo factors :oH~ Controlled ovarian Previous Infertility treatments Quality hyperstimulation Age Stage of Development !OM~ High order multiples Co morbid diagnosis 
Duration of Infertility 
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